- $5.26bn
- $5.65bn
- €1.19bn
Corrected: BRIEF-Stevanato Q2 Net Income EUR 23 Million
SCHOTT Pharma jumps as DB ups to 'buy' on growth prospects
Italy's Stevanato Q1 revenue rises more than expected, helped by GLP-1 demand
Italy's Stevanato Q4 revenue beats on BDS unit strength
Brief: Stevanato Q4 Net Income EUR 47.6 Million
Brief: Stevanato Group To Report Fourth Quarter And Fiscal Year 2025 Financial Results On March 4, 2026
Stevanato Group Q3 revenue beats analyst expectations
Stevanato Group SpA reports results for the quarter ended June 30 - Earnings Summary
Brief: Stevanato Q2 Net Income EUR 29.7 Million Vs. IBES Estimate EUR 29.2 Million
Brief: Stevanato Group Secures €200 Million In Financing From Bnl BNP Paribas, Cassa Depositi E Prestiti, And Banco Bpm To Fund Ongoing Capex Investments In Italy And U.S.
Stevanato Group SpA reports results for the quarter ended March 31 - Earnings Summary
Stevanato Group SpA reports results for the quarter ended December 31 - Earnings Summary
Stevanato Group SpA expected to post earnings of 18 cents a share - Earnings Preview
Abating headwinds - UBS upgrades Schott Pharma to 'buy'
Stevanato Group SpA reports results for the quarter ended in January 1 - Earnings Summary
Brief: Stevanato Q3 Net Income EUR 30 Million Vs. IBES Estimate EUR 33.8 Million
Brief: Gerresheimer, Stevanato Group And Schott Pharma Announce Strategic Industry "Alliance For RTU"
Stevanato Group SpA reports results for the quarter ended in June - Earnings Summary
Brief: Stevanato Q2 Net Income EUR 20.6 Million Vs. IBES Estimate EUR 27.5 Million